Researchers have identified a potential fresh target for treating Alzheimer’s disease by focusing on the brain’s internal waste-disposal system. By targeting a specific receptor known as DDR2, a team of scientists has demonstrated that it is possible to clear toxic protein clumps from the brains of mice, resulting in measurable improvements in memory and learning capabilities.
This novel approach to clearing brain waste shows promise for Alzheimer’s due to the fact that it moves beyond simply removing amyloid plaques—the hallmark of the disease—and instead focuses on enhancing the “glymphatic system,” the biological plumbing that flushes metabolic debris from the central nervous system. While previous drugs have successfully cleared amyloid, they have often failed to produce significant clinical improvements in patient symptoms.
The research, led by Jia Li at Guangzhou Medical University in China, suggests that blocking the DDR2 pathway may simultaneously reduce the production of amyloid-beta proteins and accelerate their removal. “If you’re blocking the DDR2 pathway, theoretically there will be less amyloid-beta protein produced and, at the same time, it will boost the waste clearance for the protein,” Li said. “So, we’re hoping it can finally reverse Alzheimer’s.”
A scanning electron micrograph of a mouse nerve cell that is affected by misfolded versions of the proteins amyloid and beta, which are thought to drive Alzheimer’s disease
LINNEA RUNDGREN/LINEAR IMAGING/SCIENCE PHOTO LIBRARY
From Lung Health to Brain Waste
The connection to Alzheimer’s came from an unexpected place: pulmonary research. DDR2 (discoidin domain receptor 2) is a receptor primarily studied for its role in lung health, specifically in conditions like pulmonary fibrosis. In the lungs, a dysfunction in the extracellular matrix—the network of proteins surrounding cells—leads to an over-accumulation of collagen, which restricts oxygen supply to the cells.
Jin Su, a researcher at Guangzhou Medical University, and her colleagues noticed a parallel in the brain. There are indications that similar dysfunction in the brain’s extracellular matrix is linked to the deposition of amyloid and tau proteins. Li noted that this restriction of oxygen could be a primary driver of the cognitive decline, specifically problems with thinking and remembering, associated with the disease.
To test this hypothesis, the team scanned human tissue databases and discovered a striking pattern: DDR2 is rarely found in healthy human brain tissue, but it is present in high abundance in the brains of those with Alzheimer’s. “We are the first to confirm that DDR2 is found in high abundance in Alzheimer’s brain tissue,” Su said.
Targeting the Cellular Drivers of Decay
The researchers identified three specific cell types that increase DDR2 expression during the progression of Alzheimer’s, each playing a role in the disease’s pathology:
- Reactive Astrocytes: Cells that surround and react to amyloid-beta clumps.
- Perivascular Fibroblasts: Cells that reveal altered activity even before the onset of clinical symptoms.
- Choroid Plexus Epithelial Cells: Cells critical for the production of cerebrospinal fluid, which is the primary vehicle for the glymphatic system’s waste-clearing process.
By targeting DDR2, the researchers believe they can address multiple points of failure in the brain’s defense system simultaneously. To achieve this, they developed a monoclonal antibody designed to eliminate these receptors. In mouse models, the treatment led to a reduction in DDR2 levels, a decrease in amyloid plaques, and a noticeably more efficient glymphatic system. Most importantly, the mice showed improved performance in spatial learning and memory tests.
Expert Perspectives and Clinical Constraints
While the results are promising, independent experts urge a measured interpretation. Shiju Gu of Harvard University described the mouse results as “fairly impressive” and noted that DDR2 is a “legit target,” but added a “big question mark” regarding the possibility of actually reversing Alzheimer’s given the extreme complexity of the human condition.
César Cunha, from the Novo Nordisk Foundation Center for Basic Metabolic Research in Denmark, pointed out a critical limitation: the mouse models used represented a rare, inherited form of the disease that appears earlier than typical cases. It remains uncertain if the antibody would be as effective in late-onset Alzheimer’s, which is far more common.
However, Su argues that the treatment could have broad efficacy. She notes that DDR2 upregulation is observed in both familial and late-onset cases, and that expression of the receptor is increased by aging and hypoxia—both of which are known risk factors for the common form of the disease.
| Factor | Effect of DDR2 Upregulation | Effect of DDR2 Blocking (Antibody) |
|---|---|---|
| Amyloid-Beta | Increased production and accumulation | Reduced production and plaques |
| Glymphatic System | Impaired waste clearance | Boosted waste clearance |
| Cognitive Function | Memory and learning deficits | Improved spatial learning/memory |
Next Steps Toward Human Treatment
The research team is now transitioning from animal models to human application. They are currently conducting a clinical trial using a specialized tracer to monitor DDR2 levels in the brains of Alzheimer’s patients. This mapping will help determine exactly where the antibody needs to be directed for maximum effect.
A significant hurdle remains the blood-brain barrier, a protective layer that prevents most large molecules from entering the brain. To solve this, the researchers are developing a smaller version of the antibody designed to cross this barrier more efficiently, potentially allowing for a non-invasive delivery method.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next confirmed checkpoint for this research involves the ongoing clinical trials to map DDR2 distribution in human patients, which will inform the dosing and delivery of the antibody candidates.
We invite you to share your thoughts on these developments in the comments below or share this story with others interested in neurological health.
